Trial Profile
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of TAK-137 in Healthy Subjects
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs TAK 137 (Primary)
- Indications Attention-deficit hyperactivity disorder; Neurological disorders; Psychiatric disorders
- Focus Adverse reactions
- Sponsors Takeda
- 05 Jun 2015 Status changed from recruiting to withdrawn prior to enrolment, as reported by ClinicalTrials.gov record.
- 01 Jan 2015 New trial record